Efficacy and Safety of the CG-100 Intraluminal Bypass Device

Recruiting N/A Interventional Study
Rectal Cancer Rectal Tumor Rectal/Anal
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
22 – 70
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
250 (estimated)
Sponsor
Colospan Ltd. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. The patient is willing to comply with protocol-specified follow-up evaluations 2. Patient 22-65 years of age at screening, or patient 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed. 3. Patie…
Contacts

Boaz Assaf

+972-9-7672518

boaz@colospan.com

CONTACT

Shelly Sharon, MSc

Shelly@colospan.com

CONTACT